NPPA Notifies New MRP for Key Cardiac, Diabetes and Antibiotic Drugs, Details
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed the retail prices of 11 formulations under the Drugs (Prices Control) Order, 2013.
The list of formulations includes Windlas Biotech/Intas Pharmaceuticals' Bisoprolol Fumarate and Telmisartan Tablets, Innova Captab/Dr. Reddy's Ceftriaxone and Sulbactam for Injection, Synokem Lifesciences/Glenmark Pharmaceuticals' Teneligliptin, Dapagliflozin, Metformin (Sustained Release) Tablets and others.
This came in exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (NPPA) has fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer and marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Table
| Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
|---|---|---|---|---|---|
| 1 | Bisoprolol Fumarate & Telmisartan Tablets | Each uncoated bilayered tablet contains: Bisoprolol Fumarate IP 2.5 mg, Telmisartan IP 40 mg | 1 Tablet | M/s Windlas Biotech Ltd. / M/s Intas Pharmaceuticals Ltd. | 10.49 |
| 2 | Bisoprolol Fumarate & Telmisartan Tablets | Each uncoated bilayered tablet contains: Bisoprolol Fumarate IP 5 mg, Telmisartan IP 40 mg | 1 Tablet | M/s Windlas Biotech Ltd. / M/s Intas Pharmaceuticals Ltd. | 12.09 |
| 3 | Ceftriaxone & Sulbactam for Injection | Each vial contains: Ceftriaxone Sodium IP eq. to Ceftriaxone 250 mg, Sulbactam Sodium IP eq. to Sulbactam 125 mg | 1 vial | M/s Innova Captab Ltd. / M/s Dr. Reddy’s Laboratories Ltd. | 65.30 |
| 4 | Ceftriaxone & Sulbactam for Injection | Each vial contains: Ceftriaxone Sodium IP eq. to Ceftriaxone 500 mg, Sulbactam Sodium IP eq. to Sulbactam 250 mg | 1 vial | M/s Innova Captab Ltd. / M/s Dr. Reddy’s Laboratories Ltd. | 104.32 |
| 5 | Ceftriaxone, Disodium Edetate & Sulbactam Powder for Solution for Infusion | Each vial contains: Ceftriaxone Sodium IP 1000 mg, Disodium Edetate IP 37 mg, Sulbactam Sodium IP eq. to Sulbactam 500 mg | 1 vial | M/s Gufic Biosciences Ltd. / M/s Criticare Division LLP | 567.13 |
| 6 | Ceftriaxone, Disodium Edetate & Sulbactam Powder for Solution for Infusion | Each vial contains: Ceftriaxone Sodium IP 2000 mg, Disodium Edetate IP 74 mg, Sulbactam Sodium IP eq. to Sulbactam 1000 mg | 1 vial | M/s Gufic Biosciences Ltd. / M/s Criticare Division LLP | 1140.26 |
| 7 | Levocetirizine Dihydrochloride & Montelukast Sodium Syrup | Each 5 ml contains: Levocetirizine Dihydrochloride IP 2.5 mg, Montelukast Sodium IP eq. to Montelukast 4 mg | 1 ml | M/s East African (I) Overseas / M/s SRK Puremed LLP | 1.48 |
| 8 | Telmisartan & Amlodipine Tablets | Each uncoated bilayer tablet contains: Telmisartan IP 80 mg, Amlodipine Besylate IP eq. to Amlodipine 5 mg | 1 Tablet | M/s Unison Pharmaceuticals Pvt. Ltd. | 16.00 |
| 9 | Telmisartan & Hydrochlorothiazide Tablets | Each uncoated bilayered tablet contains: Telmisartan IP 40 mg, Hydrochlorothiazide IP 12.5 mg | 1 Tablet | M/s Swiss Garnier Life Sciences / M/s SRK Puremed LLP | 7.52 |
| 10 | Cefixime & Ofloxacin Oral Suspension | Each 5 ml contains: Cefixime trihydrate IP eq. to Cefixime 50 mg, Ofloxacin IP 50 mg | 1 ml | M/s Prosperity Drugs Pvt. Ltd. / M/s Cachet Pharmaceuticals Pvt. Ltd. | 1.74 |
| 11 | Teneligliptin, Dapagliflozin, Metformin (SR) Tablets | Each bilayer tablet contains: Teneligliptin 20 mg, Dapagliflozin 10 mg, Metformin Hydrochloride SR 500 mg | 1 Tablet | M/s Synokem Lifesciences Pvt. Ltd. / M/s Glenmark Pharmaceuticals Ltd. | 12.15 |
The notification further added
(a) The manufacturer of the above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above-mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of the retail price of such a formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in columns
(3) & (5) thereof, the price order(s) fixing the retail price of the formulation with the specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
To view the notice, click the link below:
Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.